FOR SUPERIOR TRANSMUCOSAL DELIVERY OF CHALLENGING DRUGS

Non invasive transmucosal delivery is attractive due to the large surface areas involved and extensive vascularization of transmucosal tissues. These routes are desirable because they avoid hepatic first-pass metabolism and other forms of pre-systemic degradation or metabolism in the GI tract. However, barriers to absorption via these routes include poor permeability, particularly for highly charged or very large molecules, enzymatic inactivation of sensitive actives, and mucocilliary clearance.

With Mistocine, it is possible to optimally deliver drugs with poor absorption potential by non-invasive routes. Mistocine uses lipid-based systems to enhance absorption via nasal, buccal, or inhalation drug delivery. Mistocine dispenses a controlled dose as a fine spray with the droplet size engineered preferentially to deposit the formulation at the desired site of absorption. Within the respective deposits, unique nano-sized carriers rapidly and effectively deliver the active agent and/or absorption enhancers directly to the membrane in an easily absorbed form.

The respective small sizes and thermodynamic stabilities of Lipocine's proprietary Mistocine carriers create liquid dispersed systems that are physically stable, which in turn enable longer shelf-lives of the product.

Mistocine is well-suited for drugs requiring rapid onsets such as acute migraine therapies and for large macromolecular drugs like proteins and peptides, which typically require co-administration of effective amounts of absorption enhancers.

Consider LipidScreen for your target compound.